摘要
小细胞肺癌(small cell lung cancer,SCLC)具有极高的增殖率、较强的早期转移倾向和较差的预后。超过三分之二的患者初诊时分期为广泛期(extensive stage-small cell lung cancer,ES-SCLC)。小细胞肺癌治疗进展缓慢,含铂化疗一直是标准治疗方案,虽然近期有效率高,但易出现耐药。近年来免疫治疗及抗血管药物的兴起,在SCLC领域出现了突破,为SCLC建立新的治疗标准。本文将SCLC的化学治疗、抗血管治疗及免疫治疗进展进行综述。
Small cell lung cancer(SCLC) has a very high proliferation rate,a strong tendency to metastasise early and a poor prognosis.More than two-thirds of patients are initially diagnosed with extensive stage(ES-SCLC).Treatment of small cell lung cancer has progressed slowly and platinum-containing chemotherapy has been the standard of care,which,although recently highly effective,is prone to drug resistance.The rise of immunotherapy and anti-vascular agents in recent years has led to breakthroughs in the field of SCLC,establishing a new standard of care for SCLC.This article reviews advances in chemotherapy,anti-vascular therapy and immunotherapy for SCLC.
作者
阿丽亚·奥斯曼
王效刚
刘俊远
帕提古力·阿尔西丁
Aliya Aosiman;WANG Xiaogang;LIU Junyuan;Patiguli Aerxiding(The Third Clinical Medical College of Xinjiang Medical University,Tumor Hospital Affiliated to Xinjiang Medical University,Xinjiang Urumqi 830011,China;Department of Thoracic Oncology,the Third Clinical Medical College of Xinjiang Medical University,Tumor Hospital Affiliated to Xinjiang Medical University,Xinjiang Urumqi 830011,China.)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第7期1362-1366,共5页
Journal of Modern Oncology
基金
新疆维吾尔自治区自然科学基金(编号:2022D01C294)。
关键词
小细胞肺癌
化疗
耐药
抗血管治疗
免疫治疗
small cell lung cancer(SCLC)
chemotherapy
drug resistant
anti-vascular therapy
immunotherapy